Non-coding recurrent mutations in chronic lymphocytic leukaemia (original) (raw)

Accession codes

Data deposits

Sequencing, expression and genotyping array data have been deposited at the European Genome-Phenome Archive (EGA, http://www.ebi.ac.uk/ega/), which is hosted at the European Bioinformatics Institute (EBI), under accession number EGAS00000000092.

Change history

• 22 October 2015

The full size image of Extended Data Fig. 8 in the HTML was incorrectly showing Extended Data Fig. 7; this has been corrected on 22 October 2015.

References

1. Gaidano, G., Foa, R. & Dalla-Favera, R. Molecular pathogenesis of chronic lymphocytic leukemia. J. Clin. Invest. 122, 3432–3438 (2012)
   Article CAS Google Scholar
2. Zenz, T., Mertens, D., Kuppers, R., Dohner, H. & Stilgenbauer, S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nature Rev. Cancer 10, 37–50 (2010)
   Article CAS Google Scholar
3. Pekarsky, Y., Zanesi, N. & Croce, C. M. Molecular basis of CLL. Semin. Cancer Biol. 20, 370–376 (2010)
   Article CAS Google Scholar
4. Hamblin, T. J., Davis, Z., Gardiner, A., Oscier, D. G. & Stevenson, F. K. Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94, 1848–1854 (1999)
   CAS PubMed Google Scholar
5. Damle, R. N. et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94, 1840–1847 (1999)
   CAS PubMed Google Scholar
6. Crespo, M. et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N. Engl. J. Med. 348, 1764–1775 (2003)
   Article CAS Google Scholar
7. Malek, S. N. The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia. Oncogene 32, 2805–2817 (2013)
   Article CAS Google Scholar
8. Döhner, H. et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. 343, 1910–1916 (2000)
   Article Google Scholar
9. Quesada, V. et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nature Genet. 44, 47–52 (2011)
   Article Google Scholar
10. Puente, X. S. et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475, 101–105 (2011)
    Article CAS Google Scholar
11. Landau, D. A. et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152, 714–726 (2013)
    Article CAS Google Scholar
12. Fabbri, G. et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J. Exp. Med. 208, 1389–1401 (2011)
    Article CAS Google Scholar
13. Ramsay, A. J. et al. POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia. Nature Genet. 45, 526–530 (2013)
    Article CAS Google Scholar
14. Damm, F. et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov. 4, 1088–1101 (2014)
    Article CAS Google Scholar
15. Rossi, D. et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood 119, 2854–2862 (2012)
    Article CAS Google Scholar
16. Ferreira, P. G. et al. Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia. Genome Res. 24, 212–226 (2014)
    Article CAS Google Scholar
17. Kulis, M. et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nature Genet. 44, 1236–1242 (2012)
    Article CAS Google Scholar
18. Oakes, C. C. et al. Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia. Cancer Discov. 4, 348–361 (2014)
    Article CAS Google Scholar
19. Hudson, T. J. et al. International network of cancer genome projects. Nature 464, 993–998 (2010)
    Article ADS CAS Google Scholar
20. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013)
    Article CAS Google Scholar
21. Khodabakhshi, A. H. et al. Recurrent targets of aberrant somatic hypermutation in lymphoma. Oncotarget 3, 1308–1319 (2012)
    Article Google Scholar
22. Pasqualucci, L. et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 412, 341–346 (2001)
    Article ADS CAS Google Scholar
23. Byrd, J. C. et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 369, 32–42 (2013)
    Article CAS Google Scholar
24. Moncunill, V. et al. Comprehensive characterization of complex structural variations in cancer by directly comparing genome sequence reads. Nature Biotechnol. 32, 1106–1112 (2014)
    Article CAS Google Scholar
25. Stephens, P. J. et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144, 27–40 (2011)
    Article MathSciNet CAS Google Scholar
26. Baca, S. C. et al. Punctuated evolution of prostate cancer genomes. Cell 153, 666–677 (2013)
    Article CAS Google Scholar
27. Rausch, T. et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 148, 59–71 (2012)
    Article CAS Google Scholar
28. Balatti, V. et al. NOTCH1 mutations in CLL associated with trisomy 12. Blood 119, 329–331 (2012)
    Article CAS Google Scholar
29. Huang, F. W. et al. Highly recurrent TERT promoter mutations in human melanoma. Science 339, 957–959 (2013)
    Article ADS CAS Google Scholar
30. Yamane, A. et al. Deep-sequencing identification of the genomic targets of the cytidine deaminase AID and its cofactor RPA in B lymphocytes. Nature Immunol. 12, 62–69 (2011)
    Article CAS Google Scholar
31. Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214–218 (2013)
    Article ADS CAS Google Scholar
32. Simonis, M., Kooren, J. & de Laat, W. An evaluation of 3C-based methods to capture DNA interactions. Nature Methods 4, 895–901 (2007)
    Article CAS Google Scholar
33. Revilla-i-Domingo, R. et al. The B-cell identity factor Pax5 regulates distinct transcriptional programmes in early and late B lymphopoiesis. EMBO J. 31, 3130–3146 (2012)
    Article CAS Google Scholar
34. Queirós, A. C. et al. A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact. Leukemia 29, 598–605 (2015)
    Article Google Scholar
35. Strefford, J. C. et al. Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2. Leukemia 27, 2196–2199 (2013)
    Article CAS Google Scholar
36. Agathangelidis, A. et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood 119, 4467–4475 (2012)
    Article CAS Google Scholar
37. Rubio-Perez, C. et al. In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities. Cancer Cell 27, 382–396 (2015)
    Article CAS Google Scholar
38. Lobry, C., Oh, P. & Aifantis, I. Oncogenic and tumor suppressor functions of Notch in cancer: it’s NOTCH what you think. J. Exp. Med. 208, 1931–1935 (2011)
    Article CAS Google Scholar
39. O'Brien, P., Morin, P., Jr, Ouellette, R. J. & Robichaud, G. A. The Pax-5 gene: a pluripotent regulator of B-cell differentiation and cancer disease. Cancer Res. 71, 7345–7350 (2011)
    Article CAS Google Scholar
40. Villamor, N. et al. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia 27, 1100–1106 (2013)
    Article CAS Google Scholar
41. Bentley, D. R. et al. Accurate whole human genome sequencing using reversible terminator chemistry. Nature 456, 53–59 (2008)
    Article ADS CAS Google Scholar
42. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760 (2009)
    Article CAS Google Scholar
43. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078–2079 (2009)
    Article Google Scholar
44. Puente, X. S. et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475, 101–105 (2011)
    Article CAS Google Scholar
45. Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Campbell, P. J. & Stratton, M. R. Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 3, 246–259 (2013)
    Article CAS Google Scholar
46. Delgado, J. et al. Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption. Haematologica 99, e231–e234 (2014)
    Article CAS Google Scholar
47. Edelmann, J. et al. High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. Blood 120, 4783–4794 (2012)
    Article CAS Google Scholar
48. Valdés-Mas, R., Bea, S., Puente, D. A., Lopez-Otin, C. & Puente, X. S. Estimation of copy number alterations from exome sequencing data. PLoS ONE 7, e51422 (2012)
    Article ADS Google Scholar
49. Bibikova, M. et al. High density DNA methylation array with single CpG site resolution. Genomics 98, 288–295 (2011)
    Article CAS Google Scholar
50. Bibikova, M. et al. Genome-wide DNA methylation profiling using InfiniumR assay. Epigenomics 1, 177–200 (2009)
    Article CAS Google Scholar
51. Aryee, M. J. et al. Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics 30, 1363–1369 (2014)
    Article CAS Google Scholar
52. Kluk, M. J. et al. Gauging NOTCH1 activation in cancer using immunohistochemistry. PLoS ONE 8, e67306 (2013)
    Article ADS CAS Google Scholar
53. van de Werken, H. J. et al. Robust 4C-seq data analysis to screen for regulatory DNA interactions. Nature Methods 9, 969–972 (2012)
    Article CAS Google Scholar
54. van de Werken, H. J. et al. 4C technology: protocols and data analysis. Methods Enzymol. 513, 89–112 (2012)
    Article CAS Google Scholar
55. Heckl, D. et al. Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nature Biotechnol. 32, 941–946 (2014)
    Article CAS Google Scholar
56. Heigwer, F., Kerr, G. & Boutros, M. E-CRISP: fast CRISPR target site identification. Nature Methods 11, 122–123 (2014)
    Article CAS Google Scholar
57. Peto, R. & Pike, M. C. Conservatism of the approximation sigma (O-E)2-E in the logrank test for survival data or tumor incidence data. Biometrics 29, 579–584 (1973)
    Article MathSciNet CAS Google Scholar

Download references

Acknowledgements

This work was funded by Spanish Ministry of Economy and Competitiveness through the Instituto de Salud Carlos III (ISCIII) and Red Temática de Investigación del Cáncer (RTICC). We are grateful to E. Santos for his continued support to this project, and N. Villahoz and M. C. Muro for their excellent work in the coordination of the CLL Spanish Consortium. C.L.-O. is an Investigator of the Botin Foundation supported by Banco Santander through its Santander Universities Global Division, and E.Ca. and D.T. are Institució Catalana de Recerca i Estudis Avançats-Academia investigators. We acknowledge Partnership for Advanced Computing in Europe (PRACE) for awarding us access to resource Marenostrum based in Spain at the BSC, the Pershing Square Sohn Cancer Research Alliance and European Union’s FP7 through the Blueprint Consortium. We are also very grateful to all patients with CLL who have participated in this study.

Author information

Author notes

1. Carlos López-Otín and Elías Campo: These authors jointly supervised this work.

Authors and Affiliations

1. Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología (IUOPA), Universidad de Oviedo, Oviedo, 33006, Spain
   Xose S. Puente, Rafael Valdés-Mas, Jesús Gutiérrez-Abril, Diana A. Puente, Víctor Quesada & Carlos López-Otín
2. Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, 08036, Spain
   Silvia Beà, Renée Beekman, Giancarlo Castellano, Guillem Clot, David Martín-García, Alba Navarro, Cristina Royo, Nuria Russiñol & Itziar Salaverría
3. Unitat de Hematología, Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, 08036, Spain
   Neus Villamor, Marta Aymerich, Anna Carrio, Dolors Colomer, Dolors Costa, Blanca González, Mónica López-Guerra, María Rozman & Elías Campo
4. Departament d’Anatomía Patològica, Microbiología i Farmacología, Universitat de Barcelona, Barcelona, 08036, Spain
   José I. Martín-Subero & Ana C. Queirós
5. Programa Conjunto de Biología Computacional, Barcelona Supercomputing Center (BSC), Institut de Recerca Biomèdica (IRB), Spanish National Bioinformatics Institute, Universitat de Barcelona, Barcelona, 08028, Spain
   Marta Munar, Josep L. Gelpí, Santiago González, Modesto Orozco, Romina Royo & David Torrents
6. Department of Experimental and Health Sciences, Research Unit on Biomedical Informatics, Universitat Pompeu Fabra, Barcelona, 08003, Spain
   Carlota Rubio-Pérez, David Tamborero & Nuria López-Bigas
7. Unidad de Genómica, IDIBAPS, Barcelona, 08036, Spain
   Pedro Jares, Anna Enjuanes & Magda Pinyol
8. Servicio de Hematología, Hospital Clínic, IDIBAPS, Barcelona, 08036, Spain
   Tycho Baumann, Julio Delgado & Armando López-Guillermo
9. Institute for Cancer Genetics, Columbia University, New York, 10032, USA
   Laura Belver & Adolfo A. Ferrando
10. Servicio de Hematología, Hospital Universitario Central de Asturias, Oviedo, 33011, Spain
    Enrique Colado & Ángel R. Payer
11. Center for Genomic Regulation (CRG), Pompeu Fabra University (UPF), Hospital del Mar Research Institute (IMIM), Barcelona, 08003, Spain
    Xavier Estivill
12. Servicio de Hematología, IBSAL-Hospital Universitario de Salamanca, Centro de Investigación del Cáncer, Universidad de Salamanca-CSIC, Salamanca, 37007, Spain
    Marcos González & Jesús M. Hernández-Rivas
13. Centro Nacional de Análisis Genómico, Parc Científic de Barcelona, Barcelona, 08028, Spain
    Marta Gut & Ivo Gut
14. Cátedra Inter-Universitaria de Derecho y Genoma Humano, Universidad de Deusto, Universidad del País Vasco, Bilbao, 48007, Spain
    Pilar Nicolás & Carlos M. Romeo-Casabona
15. Structural Biology and Biocomputing Programme, Spanish National Cancer Research Centre (CNIO), Spanish National Bioinformatics Institute, Madrid, 28029, Spain
    David G. Pisano & Alfonso Valencia
16. Institute of Applied Biosciences, Center for Research and Technology Hellas, Thermi, 57001, Thessaloniki, Greece
    Kostas Stamatopoulos
17. Department of Molecular Biology, Faculty of Science, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen, Nijmegen, 6500 HB, The Netherlands
    Hendrik G. Stunnenberg
18. Servicio de Hematología, Hospital Clínico de Valencia, Valencia, 46010, Spain
    María J. Terol

Authors

1. Xose S. Puente
   You can also search for this author inPubMed Google Scholar
2. Silvia Beà
   You can also search for this author inPubMed Google Scholar
3. Rafael Valdés-Mas
   You can also search for this author inPubMed Google Scholar
4. Neus Villamor
   You can also search for this author inPubMed Google Scholar
5. Jesús Gutiérrez-Abril
   You can also search for this author inPubMed Google Scholar
6. José I. Martín-Subero
   You can also search for this author inPubMed Google Scholar
7. Marta Munar
   You can also search for this author inPubMed Google Scholar
8. Carlota Rubio-Pérez
   You can also search for this author inPubMed Google Scholar
9. Pedro Jares
   You can also search for this author inPubMed Google Scholar
10. Marta Aymerich
    You can also search for this author inPubMed Google Scholar
11. Tycho Baumann
    You can also search for this author inPubMed Google Scholar
12. Renée Beekman
    You can also search for this author inPubMed Google Scholar
13. Laura Belver
    You can also search for this author inPubMed Google Scholar
14. Anna Carrio
    You can also search for this author inPubMed Google Scholar
15. Giancarlo Castellano
    You can also search for this author inPubMed Google Scholar
16. Guillem Clot
    You can also search for this author inPubMed Google Scholar
17. Enrique Colado
    You can also search for this author inPubMed Google Scholar
18. Dolors Colomer
    You can also search for this author inPubMed Google Scholar
19. Dolors Costa
    You can also search for this author inPubMed Google Scholar
20. Julio Delgado
    You can also search for this author inPubMed Google Scholar
21. Anna Enjuanes
    You can also search for this author inPubMed Google Scholar
22. Xavier Estivill
    You can also search for this author inPubMed Google Scholar
23. Adolfo A. Ferrando
    You can also search for this author inPubMed Google Scholar
24. Josep L. Gelpí
    You can also search for this author inPubMed Google Scholar
25. Blanca González
    You can also search for this author inPubMed Google Scholar
26. Santiago González
    You can also search for this author inPubMed Google Scholar
27. Marcos González
    You can also search for this author inPubMed Google Scholar
28. Marta Gut
    You can also search for this author inPubMed Google Scholar
29. Jesús M. Hernández-Rivas
    You can also search for this author inPubMed Google Scholar
30. Mónica López-Guerra
    You can also search for this author inPubMed Google Scholar
31. David Martín-García
    You can also search for this author inPubMed Google Scholar
32. Alba Navarro
    You can also search for this author inPubMed Google Scholar
33. Pilar Nicolás
    You can also search for this author inPubMed Google Scholar
34. Modesto Orozco
    You can also search for this author inPubMed Google Scholar
35. Ángel R. Payer
    You can also search for this author inPubMed Google Scholar
36. Magda Pinyol
    You can also search for this author inPubMed Google Scholar
37. David G. Pisano
    You can also search for this author inPubMed Google Scholar
38. Diana A. Puente
    You can also search for this author inPubMed Google Scholar
39. Ana C. Queirós
    You can also search for this author inPubMed Google Scholar
40. Víctor Quesada
    You can also search for this author inPubMed Google Scholar
41. Carlos M. Romeo-Casabona
    You can also search for this author inPubMed Google Scholar
42. Cristina Royo
    You can also search for this author inPubMed Google Scholar
43. Romina Royo
    You can also search for this author inPubMed Google Scholar
44. María Rozman
    You can also search for this author inPubMed Google Scholar
45. Nuria Russiñol
    You can also search for this author inPubMed Google Scholar
46. Itziar Salaverría
    You can also search for this author inPubMed Google Scholar
47. Kostas Stamatopoulos
    You can also search for this author inPubMed Google Scholar
48. Hendrik G. Stunnenberg
    You can also search for this author inPubMed Google Scholar
49. David Tamborero
    You can also search for this author inPubMed Google Scholar
50. María J. Terol
    You can also search for this author inPubMed Google Scholar
51. Alfonso Valencia
    You can also search for this author inPubMed Google Scholar
52. Nuria López-Bigas
    You can also search for this author inPubMed Google Scholar
53. David Torrents
    You can also search for this author inPubMed Google Scholar
54. Ivo Gut
    You can also search for this author inPubMed Google Scholar
55. Armando López-Guillermo
    You can also search for this author inPubMed Google Scholar
56. Carlos López-Otín
    You can also search for this author inPubMed Google Scholar
57. Elías Campo
    You can also search for this author inPubMed Google Scholar

Contributions

The Chronic Lymphocytic Leukaemia Genome consortium contributed to this study as part of the International Cancer Genome Consortium. Investigator contributions are as follows: T.B., J.D., A.L.-G., A.R.P., M.G. and J.M.H.-R. contributed to sample collection and clinical annotation; M.R., N.V., E.Ca., E.Co., J.M.H.-R. and M.G. were the pathologists who reviewed and confirmed the diagnoses; P.N., C.M.R.-C. and M.A. prepared and supervised the bioethical requirements; M.P., A.E. and C.R. processed samples and performed validation analysis; M.G., I.G. and D.A.P. were responsible for generating libraries, performing exome capture and sequencing; S.B., D.To., M.M., S.G., I.S., G.C., D.M.-G., A.C., X.E. and D.Cos. analysed copy number alterations and structural variants; X.S.P., R.V.-M., J.G.-A. and V.Q. developed the bioinformatic pipeline for analysis of somatic mutations and performed functional data integration; D.Col., M.L.-G. and B.G. were responsible for downstream validation analysis and functional studies; A.N. and K.S. analysed IG gene rearrangements and stereotypes; J.I.M.-S., A.C.Q., G.C., R.B., R.G., N.R., H.G.S. and P.J. performed epigenetic and transcriptomic analysis and 4C-seq experiments; L.B. and A.A.F. performed enhancer analysis and CRISPR experiments; N.V., T.B., A.L.-G. and E.Ca. performed clinical and biological studies; J.L.G., R.R., M.O., D.G.P. and A.V. were in charge of bioinformatics data management; N.L.-B., C.R.-P. and D.Ta. contributed to pathway analysis and in silico prescription. X.S.P., C.L.-O. and E.Ca. directed the research, analysed the data and wrote the manuscript.

Corresponding authors

Correspondence toCarlos López-Otín or Elías Campo.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Extended data figures and tables

Extended Data Figure 1 Molecular characterization of CLL and MBL subtypes.

a, CLL and MBL cases are divided according to the somatic hypermutation mutational status of their clonotypic IGHV genes into IGHV-MUT (black) and IGHV-UNMUT (grey) subgroups. Clinical and molecular data from 506 cases profiled with four different platforms are shown. Chromosome 13 is shown in detail. Und, undetermined. b, Box plot showing the total number of somatic mutations identified in IGHV-MUT and IGHV-UNMUT cases by WGS (*P < 3 × 10−8). c, Main mutational signatures identified by WGS. d, Relationship between total number of mutations and contribution of signature 2 and the IGHV-status of tumours (red: IGHV-MUT; blue: IGHV-UNMUT; grey: undetermined).

Extended Data Figure 2 Distribution of CNAs and structural variants in 506 cases of CLL and MBL.

a, The total number of CNAs detected per case is indicated on top. Clinicobiological characteristics of patients (CLL/MBL and IGHV status) are shown on the middle row (MBL and IGHV-UNMUT depicted with green lines), together with the presence of chromothripsis. The main DNA copy number alterations identified are shown on the bottom. The presence of a deletion is indicated by a red line, homozygous deletion by a Bordeaux colour, blue lines indicate the presence of a gain, translocation t(14;18) is shown in green, grey lines represent the absence of alteration, and white lines indicate that no information is available for the t(14;18) for that particular case. b, Circular diagram representation of the distribution of structural variants detected in 148 WGS CLL samples. Displayed in the outer layer we show recurrence in CNAs, followed by all the breakpoints derived from large ( > 100 bp) intra- and inter-chromosomal rearrangements (dark blue) in the inner layer. For clarity, we have set the scale of CNAs to 20%, as the maximum, showing sequence gains and losses, as positive (blue) and negative (red) values, respectively. Rearrangements are displayed in absolute counts, indicating that the values in each of the regions do not reflect the recurrence among samples, as some regions with high values derive from one or two cases, normally with complex karyotypes. We highlighted with dashed squares those regions (3p21, 11q23, 13q14, 14q32 and 18q21) with rearrangements observed in more than 5% of cases with WGS. As to rearrangement events, of a total of 358 breakpoints were detected across all 148 samples, 41% of them correspond to interchromosomal translocations, while 59% occurred within chromosomes. Chromosomes 11 and 13 appear as the most rearranged, entailing 25% of all the breaks, followed by chromosomes 3 and 6 (with 8% each). Regarding interchromosomal rearrangements chromosomes 6, 8, 13 and 14 appear as the most translocated, being involved in 32% of all translocations observed. Recurrent breakpoints are indicated by arrows: black arrows for rearrangements affecting 18q21 and BCL2 (four cases with 14q32 and one case with 2p11) and blue arrows for rearrangements affecting 13q14 (nine cases with different chromosomes).

Extended Data Figure 3 Schematic view of the translocations involving BCL2 and patterns of complex structural variants in the WGS of a CLL case.

a, A total of nine translocations t(14;18)(q32;q21) were identified, resulting in the fusion of the IGH enhancer on the 3′ UTR of BCL2, as well as one translocation between the IGK locus on chromosome 2, t(2;18)(p11;q21), which affected the promoter region of BCL2. Cases with these translocations had multiple somatic mutations in the 5′-region of BCL2 (arrowheads and lollipops). RNA-seq data analysis revealed an allelic imbalance, with the rearranged allele usually much more expressed that the germline allele (pie-charts within lollipops showing in red the mutant allele fraction detected by RNA-seq for each somatic mutation), probably reflecting the effect of the translocation on the expression of BCL2 and recruitment of the SHM machinery to this locus. b, Gene expression analysis revealed that the presence of the t(14;18)(q32;q21) resulted in overexpression of BCL2 in these cases when compared with other CLL or MBL cases. c, FISH analysis of CLL cells from case 151 using a dual colour fusion probe for IGH (green) and BCL2 (red). Fusion signals are indicated with arrows. d, Case numbers and genomic coordinates for the detected translocations between immunoglobulin genes and BCL2. e, Circular representation of structural variants detected in six CLL tumours with complex rearrangements including four cases with chromoplexia (samples 16, 141, 294 and 753), chromothripsis (sample 880) and combined (sample 853). Chromosomes are represented in the outer layer, regions lost (red) and gained (blue) detected by SNP arrays are shown in the inner layer. Inter and intrachromosomal rearrangements are represented as black and blue lines, respectively. f, Reconstruction at base pair resolution of the resulting reorganized chromosomes in case 853 including der(X) in yellow, der(2) in dark blue, der(8) in green, and der(11) in red. In these reconstructions, only reorganized fragments larger than 100 bp are represented unless they involve interchromosomal translocations. Rearranged regions are not drawn to scale. Arrows denote inverted fragments relative to their normal and original orientation. Flanking portions of the derivative chromosomes without detected rearrangements are collapsed and shown as broken boxes. Estimated sizes (in Mb) for the resulting derivative chromosomes are shown on the left side, including the fraction (percentage) relative to the corresponding normal chromosome size. Asterisks indicate breakpoints that have been experimentally studied and verified. Genes disrupted by breakpoints are displayed on the left side of each of the proposed derivative chromosomes in purple. g, Whole-chromosome painting confirmed the sequencing reconstruction proposed in b. Simultaneous painting of chromosome 8 (green) and 11 (red) shows a normal chromosome 11 and a shorter chromosome der(11) as well as a normal chromosome 8 and der(8) that contains a fragment of chromosome 11 inserted below the centromeric region. In addition, a small fragment of chromosome 8 is detected in the telomeric region of derivative chromosome 2.

Extended Data Figure 4 Effect of activating mutations in the 3′ UTR non-coding region of NOTCH1.

a, Proportion of RNA-seq reads supporting an aberrant splicing in cases with or without mutations in the 3′ UTR of NOTCH1 (**P < 0.01). b, Immunohistochemistry of CLL cells with antibodies against NOTCH1 showing the nuclear accumulation of NOTCH1 in cells with coding or non-coding mutations in NOTCH1 (case numbers are indicated inside). Original magnification, ×100. c, Clinical and biological features of patients with NOTCH1 mutations. Characteristics of patients with truncating mutations in the coding region of NOTCH1, in the 3′ UTR of NOTCH1, or without mutations in NOTCH1 for Binet, ZAP70, CD38, IGHV status and trisomy 12.

Extended Data Figure 5 Effect of mutations in the PAX5 enhancer on gene expression.

Comparative analysis of gene expression between IGHV-MUT CLL tumours with or without (WT) mutations in the PAX5 enhancer for 15 genes located around the recurrently mutated enhancer in CLL and MBL samples.

Extended Data Figure 6 PAX5 enhancer deletion downregulates PAX5 expression in human B cell lines.

a, PCR analysis of CRISPR/Cas9 deletion of PAX5 enhancer in lymphoblastoid B cells (left) and RAMOS cells (right). b, Quantitative RT–PCR (RT–qPCR) analysis of PAX5 expression in PAX5 enhancer deleted lymphoblastoid B cells (left) and RAMOS cells (right). Bars represent mean relative PAX5 mRNA levels after normalization to GAPDH expression and relative to wild-type cells. Errors bars represent the s.d. between technical triplicates of CRISPR/Cas9-induced mutations in PAX5 enhancer in lymphoblastoid B cells (left) and RAMOS cells (right). c, PCR analysis of CRISPR/Cas9-introduced mutations in the PAX5 enhancer in lymphoblastoid B cells (left) and RAMOS cells (right). d, RT–qPCR analysis of PAX5 expression in PAX5-enhancer-mutated lymphoblastoid B cells (left) and RAMOS cells (right). Bars represent mean relative PAX5 mRNA levels after normalization to GAPDH expression and relative to wild-type cells. Error bars represent the s.d. between technical triplicates (*P < 0.05; **P < 0.01).

Extended Data Figure 7 Distribution of genetic, epigenetic and expression features in CLL.

Distribution of genetic features, family of IGHV rearrangements and BCR stereotypes in naive cell-like CLL cases, intermediate CLL and memory-cell-like CLL cases. a, Frequency of driver mutations. b, c, Copy number alterations (b) and contribution of signature 2 (c) according to the epigenetic classification (green: naive-like; red: memory-like; yellow: intermediate). MBL patients were excluded from this analysis. d, Usage of IGHV families. e, Proportion of cases with stereotyped IGHV sequences. f, Number of cases of each of the stereotyped subsets identified in our series. For the analysis shown in e and f, both CLL and MBL patients were merged. The asterisk on the top of the bars in a and b indicates that the frequency of the genetic feature is higher than expected by chance in one particular epigenetic subgroup (P < 0.05). CP, chromoplexy; CT, chromothripsis. g, Relationship between genetic and epigenetic alterations in CLL. Correlation between the total number of somatic mutations detected by WGS per case and the number of CpGs showing differential methylation per case as compared to naive B cells (r = 0.64, P < 0.001). h, Correlation between the contribution of signature 2 mutations and the number of differential CpGs as in a. Tumours are coloured according to their IGHV status. i, Comparative analysis of CLL and MBL. Principal component analysis of differential methylation (up) and gene expression (bottom) data derived from either CLL tumours or MBL samples, reveals that MBL samples usually clustered with their corresponding IGHV-status CLL samples.

Extended Data Figure 8 Kaplan–Meier plot of time to first treatment stratified by the type of aberration in ATM, BIRC3, TP53 and ZNF292 genes.

TTT curves of the 386 untreated patients with Binet stage A or B. Cases are stratified according to the gene mutation status: wild type (green line), mutated and mutated+deleted (Mut, blue line) or deleted (Del, red line). The log-rank _P_-;values comparing the mutated (blue line) and the deleted (red line) cases are shown.

Extended Data Table 1 Clinical information at the time of sampling of 452 patients with CLL and 54 with MBL

Full size table

Extended Data Table 2 Recurrently mutated genes in CLL and MBL by WGS, WES or CNAs

Full size table

Supplementary information

PowerPoint slides

Rights and permissions

About this article

Cite this article

Puente, X., Beà, S., Valdés-Mas, R. et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia.Nature 526, 519–524 (2015). https://doi.org/10.1038/nature14666

Download citation

• Received: 23 February 2015
• Accepted: 15 June 2015
• Published: 22 July 2015
• Issue Date: 22 October 2015
• DOI: https://doi.org/10.1038/nature14666